Navigation Links
Key Caldolor(R) Orthopedic Data to Be Presented at American Academy of Orthopaedic Surgeons' Annual Meeting
Date:3/4/2010

NASHVILLE, Tenn., March 4 /PRNewswire-FirstCall/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX) today announced that results from a clinical trial of Caldolor® (ibuprofen) Injection will be presented at the 2010 Annual Meeting of the American Academy of Orthopaedic Surgeons (AAOS) in New Orleans, Louisiana.

A poster presentation of the study, entitled "A Multi-Center, Randomized, Double-Blind Placebo-Controlled Trial of Ibuprofen Injection (IVIb) for Treatment of Pain in Post-Operative Orthopedic Adult Patients," will be presented daily March 10 – 12 from 12:00 p.m. to 1:00 p.m. Neil Singla, M.D., Chief Executive Officer of Lotus Clinical Research, Inc., is the principal investigator of the study and Byron Kaelin, BSHS, RN, Manager of Clinical Operations at Cumberland Pharmaceuticals Inc., is the presenting author.

The data from this study demonstrates that pre- and post-operative administration of Caldolor is effective in treating pain and reducing morphine utilization in adult patients undergoing orthopedic surgery. No significant differences in adverse events were seen between Caldolor and placebo, including any that would suggest renal, cardiac or bleeding complications. Caldolor is the first and only injectable product approved in the United States to treat pain and fever.

Concurrent with the presentation, the poster will be available on Cumberland Pharmaceuticals' website at http://investor.shareholder.com/cpix/events.cfm. Copies also can be obtained by contacting the Company at 615-255-0068.

The AAOS Annual Meeting is the world's largest meeting of orthopaedic surgeons and allied health professionals and serves as a forum for sharing the latest information on orthopaedic treatments, advances and research. For more information, visit www.aaos.org.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It is the first FDA approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticaria, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a Tennessee-based specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's product portfolio includes Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning and Kristalose® (lactulose) for Oral Solution, a prescription laxative. The Company also recently launched Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States. Cumberland is dedicated to providing innovative products which improve quality of care for patients. The Company completed the initial public offering of its common stock in August 2009. For more information on Cumberland Pharmaceuticals, please visit www.cumberlandpharma.com.

SOURCE Cumberland Pharmaceuticals Inc.

Back to top

RELATED LINKS
http://www.cumberlandpharma.com

'/>"/>

SOURCE Cumberland Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cumberland Pharmaceuticals Donates Caldolor(R) to Haitian Relief Effort
2. New Caldolor(R) (ibuprofen) Injection Data to Be Presented at 44th American Society of Health-System Pharmacists Meeting
3. Caldolor(R) (Ibuprofen) Injection Demonstrates Significant Fever Reduction in Hospitalized Burn Patients
4. Cumberland Pharmaceuticals and Phebra Pty Ltd. Sign Exclusive Agreement for Commercialization of Caldolor(R) in Australia and New Zealand
5. 2nd Annual Orthopedic Design & Technology Forum Returns April 28 to the FedEx Institute of Technology, University of Memphis
6. Hanger Orthopedic Group, Inc. Reports an Increase of 42.3% in Earnings Per Share, to $0.37 on a 10.6% Sales Increase, for the Fourth Quarter 2009
7. Hanger Orthopedic Group, Inc. Announces 2009 Year-End Earnings Release Conference Call
8. Medstrat Partners with Major Orthopedic Company
9. Hanger Orthopedic Group Increases Q4 2009 Sales and EPS Guidance
10. Wound Management Technologies, Inc. Targets Multi-Billion Dollar Biomaterials Market; Releases Update on Resorbable Orthopedics
11. Reportlinker Adds Top Ten Worlds Leading Orthopedics Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... , Feb. 17, 2017   ... to protecting the rights of victims injured by ... prompted regulators to call for better reporting. Congress ... Safety concerns involving power morcellators and ... (FDA) to investigate how hospitals report injuries and ...
(Date:2/17/2017)... According to a new market research report ... Application (Cleanroom Monitoring, Contamination Monitoring of Liquids), and End User (Healthcare ... the market is expected to reach USD 330.6 Million by 2021 ... from 2016 to 2021. Continue Reading ... ...
(Date:2/17/2017)... 17, 2017 Research and Markets has announced the ... report to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology:
(Date:2/17/2017)... ... February 17, 2017 , ... ... sustainable systems change designed to further positively impact the health and wellness of ... has long considered it our duty to seriously consider releasing our assets beyond ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Prevent a Warning Letter, **An FDAnews Webinar**, Feb. 23, 2017 — 1:30 p.m. ... distinguish between corrective action (CA) and preventive action (PA)? , The methods share ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... operations executives and focusing on all facets of clinical trial planning and management. ... , patient engagement, and more. In addition, attendees stopping by Pharmica’s booth were ...
(Date:2/17/2017)... ... February 17, 2017 , ... The Mason Pasquin Agency, ... and business owners in and around the Hampton Roads metropolitan region, is joining ... forms of domestic violence. , There are multiple categories of domestic violence – ...
(Date:2/16/2017)... AL (PRWEB) , ... February 17, 2017 , ... ... protection assistance and financial planning services to families and entrepreneurs in the Birmingham ... a local adoptive mother who needs assistance with her medically challenged son, Anius. ...
Breaking Medicine News(10 mins):